Our technology is a revolutionary stem cell-matrix agent, biodegradable and biocompatible for the treatment of eye diseases. It is designed for cell protection, maturation and targeted delivery in multiple compartments of the eye.
Our team has more than 30 years of expertise in tissue engineering, retinal regeneration, biomaterials, and regenerative medicine from universities such as Harvard Medical School, MIT, Imperial College and Yale University.
We are committed to restore vision to blind patients all around the world. Each project and pipeline in our company always aims at easing the disease burden for blind patients and creating innovative treatments.
Retinitis Pigmentosa, or RP, is characterized by the loss of peripheral vision and the difficulty of seeing at night. At late-stage, patients also loose their central vision, leading to blindness. It is estimated that approximately 80,000 patients are affected by RP in the United States as of 2021. There are currently no therapies available to treat late stage RP.
Glaucoma is the second leading cause of blindness worldwide and it affects more than 2.7 million people above the age of 40 in US. The damage onto optic nerve due to high pressure causes the patient to lose vision slowly starting from the peripheral. Presently, there is no treatment available for patients in late stage of the disease.
Age related macular degeneration, also knows as “AMD” causes loss of vision in people over age of 60. The macula (part of the retina) starts to degenerate making it difficult for patients to recognize faces and perform normal activity such as driving or reading. There are approximately 15 million people in US with reported AMD and approximately more than 1.7 million have advanced for of the AMD.
InGel Therapeutics
Copyright © 2022 InGel Therapeutics - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.